Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that the Phase 3 FURVENT trial (NCT05607550) evaluating firmonertinib monotherapy in previously untreated, locally advanced or metastatic non‑squamous NSCLC harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression‑free survival (PFS) by blinded independent central review (BICR). Secondary endpoints — PFS by investigator’s assessment and confirmed objective response rate (ORR) by BICR — nonetheless showed clinical benefit, and an immature trend toward improved overall survival (OS) was observed, with no new safety signals.
Trial Outcome Summary
| Item | Detail |
|---|---|
| Trial | FURVENT – Phase 3, randomized, controlled (NCT05607550) |
| Population | Previously untreated, locally advanced/metastatic non‑squamous NSCLC with EGFR exon 20 insertion mutations |
| Intervention | Firmonertinib monotherapy, 240 mg and 160 mg arms, vs. control (regimen not disclosed) |
| Primary Endpoint | PFS by BICR — not met |
| Secondary Endpoints | Clinical benefit observed in PFS (investigator assessment) and confirmed ORR (BICR) |
| Overall Survival | Trend toward improvement; data not yet mature |
| Safety | Consistent with previous firmonertinib studies; no new safety signals |
| Next Steps | Allist and partner ArriVent to evaluate the complete FURVENT dataset and determine next steps |
Drug Profile & Mechanism of Action
- Molecule: Firmonertinib — an oral third‑generation EGFR tyrosine kinase inhibitor described by the company as thoroughly validated “from clinical research to clinical practice.”
- Target: EGFR exon 20 insertion mutations — a historically hard‑to‑treat subclass in which the insertion narrows the ATP‑binding pocket and confers resistance to most first‑ and second‑generation EGFR TKIs.
- Commercial Footprint: Multiple firmonertinib indications are already approved in China and included in national reimbursement (NRDL); several additional indications are under development.
- Strategic Partnership: Allist is collaborating with ArriVent BioPharma (NASDAQ: AVBP), led by Dr. Yao, to advance ongoing clinical programs and collaborative product development for firmonertinib.
Clinical Evidence – FURVENT Phase 3 Trial
PFS and ORR by blinded independent central review (BICR):
| Endpoint (BICR) | Firmonertinib 240 mg | Firmonertinib 160 mg | Control |
|---|---|---|---|
| Median PFS | 11.0 months | 8.4 months | 9.5 months |
| HR vs. control (95% CI) | 0.75 (0.55–1.02) | 0.91 (0.67–1.25) | — |
| Confirmed ORR | 60% | 35% | 33% |
PFS and ORR by investigator’s assessment:
| Endpoint (Investigator) | Firmonertinib 240 mg | Firmonertinib 160 mg | Control |
|---|---|---|---|
| Median PFS | 11.1 months | 8.3 months | 7.1 months |
| HR vs. control (95% CI) | 0.61 (0.46–0.81) | 0.86 (0.65–1.14) | — |
| Confirmed ORR | 61% | 41% | 28% |
The 240 mg arm delivered the strongest signal: a statistically meaningful 39% reduction in progression risk by investigator assessment (HR 0.61; CI excludes 1.0) and a confirmed ORR of 60–61%, nearly double the control arm’s 28–33%. The BICR HR of 0.75 (0.55–1.02) narrowly crossed the significance boundary, explaining the primary‑endpoint miss.
Safety: Grade ≥3 treatment‑emergent adverse events (TEAEs) occurred in 52%, 53%, and 55% of patients in the firmonertinib 240 mg, 160 mg, and control groups, respectively; grade ≥3 treatment‑related adverse events (TRAEs) in 26%, 22%, and 40%, respectively — a numerically lower treatment‑related burden than control at both doses.
Market Impact & Outlook
- Unmet Need: EGFR exon 20 insertions account for a small but clinically significant share of EGFR‑mutant NSCLC in published literature, and until recently were largely excluded from the benefit of classic EGFR TKIs; the first‑line setting is now contested by antibody‑based regimens such as amivantamab plus chemotherapy.
- Interpretation Risk: A primary‑endpoint miss by BICR typically complicates first‑line filing strategy, yet the 240 mg dose’s response‑rate doubling and OS trend give Allist and ArriVent defensible grounds to continue development — the companies say they are reviewing the complete dataset before deciding next steps.
- Management Conviction: Vice Chairman and Deputy GM Jie Hu reaffirmed three “firm” commitments: expanding firmonertinib’s indication footprint, strengthening innovative‑drug R&D, and deepening collaboration with ArriVent on all ongoing programs.
- Platform Value: With multiple reimbursed approvals already on the market in China, firmonertinib remains a core Allist franchise asset; FURVENT’s readout affects the ex‑China and first‑line ex20ins opportunity rather than the drug’s established base.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory strategy, and commercial expectations for firmonertinib, including planned analyses of the complete FURVENT dataset. Actual results may differ materially due to risks including further data maturation, regulatory review outcomes, competitive dynamics in EGFR exon 20 insertion NSCLC, and the success of the Allist–ArriVent collaboration. This summary is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech
